# Angiotensin receptor blockers (ARBs)

Drug · id `cardio:angiotensin-receptor-blockers-arbs` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: ARBs; ARB; Angiotensin II receptor blockers; Angiotensin receptor blockers; Angiotensin receptor blocker

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A class of medicines that block the receptor that angiotensin II acts on. MeSH notes that some of them are used as blood pressure lowering agents. The US label read for one ARB lists high blood pressure in adults and children, lowering the risk of stroke in people who have high blood pressure and left ventricular hypertrophy (the label says there is evidence that this benefit does not apply to Black patients), and a kidney disease of type 2 diabetes in people with a history of high blood pressure. It also carries a boxed warning that these drugs can cause injury and death to the developing fetus.

## Technical summary

Class page. MeSH descriptor D047228 (Angiotensin II Type 1 Receptor Blockers, last updated 2020-05-27) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name losartan potassium tablet (application NDA020386, effective 2026-01-20 in openFDA). It calls the medicine an angiotensin II receptor blocker. Its first list of uses says children greater than 6 years old, while the detailed hypertension text says pediatric patients 6 years of age and older; both are kept side by side. The label says the stroke benefit has evidence that it does not apply to Black patients. A separate claim records the boxed warning on fetal toxicity; the recipient of that risk is the fetus. One label stands for one product, so other members of the class may list other uses, and no other label was read. This page gives no dose, no trial result and no guideline statement. Medicines of the class that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking an ARB during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of COZAAR carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\]. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: The boxed warning title and its fetal-injury statement.
  2. Background: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: Effective date of the label text read, 20260120.

## Context: People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB

Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with hypertension and left ventricular hypertrophy, and patients with type 2 diabetes, a history of hypertension, an elevated serum creatinine and proteinuria.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of COZAAR (losartan potassium tablets, Organon LLC, application NDA020386; the version dated 2026-01-20 in openFDA) calls the medicine an angiotensin II receptor blocker (ARB). It lists treating hypertension in adults and pediatric patients 6 years of age and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. The label says there is evidence that the stroke benefit does not apply to Black patients. MeSH says the class antagonizes the angiotensin II type 1 receptor and that some of its members are used as antihypertensive agents.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with hypertension and left ventricular hypertrophy, and patients with type 2 diabetes, a history of hypertension, an elevated serum creatinine and proteinuria.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's first list says children greater than 6 years old, while its detailed hypertension text says pediatric patients 6 years of age and older; the two were not reconciled. Other ARB labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: The label sentences that call the medicine an ARB and list its uses.
  2. Background: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: Effective date of the label text read, 20260120.
  3. Supports: MeSH scope note for descriptor D047228 (Angiotensin II Type 1 Receptor Blockers) (Dataset, edition MeSH linked-data record of the preferred concept M0456879 of descriptor D047228, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0456879>
     Locator: scopeNote.@value. Retrieved 2026-11-09T13:15:41Z. Source state: Current. Version fingerprint: 854b15d2482adbea17ec622f381141506c3f5275a47ddce16330c4c2365c6e66.
     How it applies: MeSH scope note: the class antagonizes the angiotensin II type 1 receptor; some are antihypertensive agents.

## Connected pages

- A US label lists treating high blood pressure as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-cozaar-label-indications` and its context]
- A US label lists diabetic kidney disease in type 2 diabetes as an indication: Diabetic kidney disease (`cardio:diabetic-nephropathy`) [a claim, not a settled fact; see claim `cardio:claim-fda-cozaar-label-indications` and its context]
- Reading path on high blood pressure that names this class; a US label of the class lists high blood pressure: From a high blood pressure reading to stroke prevention (`cardio:reading-path-high-bp`)
- Patient guide on high blood pressure that names this class; a US label of the class lists high blood pressure: Newly diagnosed high blood pressure (`cardio:guide-new-high-blood-pressure`)
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Heart failure medicine regimen: Four-class medicine regimen in heart failure (guideline-directed medical therapy) (`cardio:hfref-four-medicine-regimen`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Candesartan (`cardio:candesartan`)
- Has subtype: Losartan (`cardio:losartan`)
- Has subtype: Olmesartan (`cardio:olmesartan`)
- Related to: Ranolazine (`cardio:ranolazine`)
- Has subtype: Telmisartan (`cardio:telmisartan`)
- Has subtype: Valsartan (`cardio:valsartan`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 14 registry trials

## Provenance

Content hash: 535c4a0337f49694655bf3902ccd148b35a5ba74b840c493a28c7c297c25318d
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
